I'm LongbridgeAI, I can summarize articles.Amgen (AMGN) rose 4.25% this week to close at $432.49. The S&P 500 fell 1.95% over the same period, leaving Amgen ahead of the benchmark by roughly 6.2 percentage points. The stock opened Monday below the prior close and drifted higher, touched a weekly low of $411.04 on Tuesday, then rallied on heavier volume through Wednesday and Thursday. It peaked at $441.
The Week
Amgen (AMGN) rose 4.25% this week to close at $432.49. The S&P 500 fell 1.95% over the same period, leaving Amgen ahead of the benchmark by roughly 6.2 percentage points. The stock opened Monday below the prior close and drifted higher, touched a weekly low of $411.04 on Tuesday, then rallied on heavier volume through Wednesday and Thursday. It peaked at $441.76 on Thursday before easing to end the week, a pattern of early weakness followed by a strong midweek push and late consolidation.
Key Events
The main story this week was rotation out of tech and into healthcare. News flow pointed to AI trade pullback and debt concerns in tech as reasons that lifted shares of large pharma names. Amgen rose 3.29% on Wednesday and another 3.01% on Thursday, with an intraday surge noted on the latter day, and helped push the Dow higher alongside UnitedHealth. Company-specific news was limited; the move was driven more by sector revaluation as investors sought defensive exposure, with competition in weight-loss drugs also drawing attention but without fresh Amgen announcements.
Analyst Ratings
A total of 34 institutions cover the stock. Eight rate it buy, four rate it over, 17 hold, two under and three sell. The consensus rating is hold, with a consensus target of $394.97828, about 8.67% below the latest price of $432.49. Targets range from $225 to $500, a wide dispersion. Amgen ranks second among 509 biotechnology companies in industry ratings coverage.
The Week Ahead
The early part of next week brings US housing and inventory data: the NAHB housing market index on Monday, housing starts and building permits on Tuesday, and EIA crude inventory numbers on Wednesday. The key event arrives later, with Amgen scheduled to report third-quarter fiscal 2026 earnings after the close on 3 November. Consensus estimates put EPS at around $4.0842 and revenue near $10.1 billion. With the stock trading near the upper end of its 60-day range, the next question is whether earnings can support the defensive bid seen this week.
In Short
This week’s rally in Amgen looks tied to defensive rotation during a broader tech pullback rather than a fresh company catalyst. On one side, the consensus target sits below the spot price and the rating mix leans conservative; on the other, price has returned to the upper end of a 60-day range and the company’s industry rating position is among the strongest. The main thing to watch is whether next quarter’s results give the move a fundamental anchor.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.